Free Trial
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$647.09 +0.06 (+0.01%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$642.96 -4.13 (-0.64%)
As of 08/29/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Key Stats

Today's Range
$642.29
$652.00
50-Day Range
$514.61
$682.78
52-Week Range
$356.14
$688.12
Volume
304,946 shs
Average Volume
714,037 shs
Market Capitalization
$51.77 billion
P/E Ratio
53.88
Dividend Yield
N/A
Price Target
$649.44
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
90th Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 90% of companies evaluated by MarketBeat, and ranked 111th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEXX Laboratories has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 53.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 53.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.27.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 4.19. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 35.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    3.13% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 6.06%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.13% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 6.06%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 30 news articles for IDEXX Laboratories this week, compared to 28 articles on an average week.
  • Search Interest

    19 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 533% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $34,293,468.00 in company stock.

  • Percentage Held by Insiders

    Only 0.98% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXX Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Leerink Partnrs Has Strong Estimate for IDXX FY2026 Earnings
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $413.44 on January 1st, 2025. Since then, IDXX stock has increased by 56.5% and is now trading at $647.09.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its earnings results on Monday, August, 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.35. The company's revenue for the quarter was up 10.6% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of IDEXX Laboratories include Vanguard Group Inc. (12.34%), State Street Corp (4.44%), Geode Capital Management LLC (3.06%) and Bamco Inc. NY (2.54%). Insiders that own company stock include Jonathan W Ayers, Jonathan Jay Mazelsky, Brian P Mckeon, Nimrata Hunt, Michael G Erickson, James F Polewaczyk, George Fennell, Kathy V Turner, Michael Lane, Sharon E Underberg, Daniel M Junius, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
8/04/2025
Today
8/30/2025
Next Earnings (Estimated)
10/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
CIK
874716
Employees
11,000
Year Founded
1983

Price Target and Rating

High Price Target
$785.00
Low Price Target
$520.00
Potential Upside/Downside
+0.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$12.01
Trailing P/E Ratio
53.88
Forward P/E Ratio
54.24
P/E Growth
4.19
Net Income
$887.87 million
Net Margins
24.41%
Pretax Margin
30.41%
Return on Equity
64.42%
Return on Assets
29.89%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
1.11
Quick Ratio
0.79

Sales & Book Value

Annual Sales
$4.04 billion
Price / Sales
12.82
Cash Flow
$12.43 per share
Price / Cash Flow
52.06
Book Value
$18.23 per share
Price / Book
35.50

Miscellaneous

Outstanding Shares
80,005,000
Free Float
79,221,000
Market Cap
$51.77 billion
Optionable
Optionable
Beta
1.49

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners